ReviewIranian biomedical journal2025
Optimizing Cancer Treatment: A Comprehensive Review of Active and Passive Drug Delivery Strategies.
Review in Iranian biomedical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Biomaterial-driven remove-remodel-repair (3R) strategy for full-cycle gastric cancer management: bibliometric mapping, preclinical evidence, and a translational roadmap.Nanoscale advances · 2026Review
- Recent Advances in Small-Molecule-Based Nanovectors for the Treatment of Colorectal Cancer.Molecules (Basel, Switzerland) · 2026Review
- Dual Anticancer and Antibacterial Applications of Active Particle Aggregates Containing Metal Phthalocyanines in Dark.International journal of molecular sciences · 2026Article
- pH-responsive Ni-MOF based nanocarriers with folic acid targeting for enhanced chemotherapeutic efficacy in breast cancer.RSC advances · 2026Article
- Multifunctional chitosan-doxorubicin nanocarriers: advancing targeted breast cancer chemotherapy.Molecular cancer · 2026Review
- Metal-Organic Framework-Based Drug Delivery Systems for Cancer Therapy: A Review.International journal of molecular sciences · 2026Review
- Polymer-doxorubicin Conjugates: Redefining Chemotherapy for Breast Cancer.Mini reviews in medicinal chemistry · 2026Article
- PAMAM dendrimers as efficient drug nanocarriers of natural compounds in breast cancer therapeutics.Frontiers in oncology · 2026Review
- Advancing cancer radiotherapy: Harnessing radiosensitizers and nanotechnology for enhanced tumor control.International journal of pharmaceutics: X · 2025Review
- Designing Oral Films Based on Beeswax: Comparative Assessment of 3D Printing and Solvent Casting.Iranian biomedical journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanocarriers as powerful tools for delivering drugs to tumors provide new strategies for cancer treatment. These delivery systems encompass a diverse variety of structures, including polymeric nanoparticles (NPs), liposomes, dendrimers, micelles, and inorganic NPs such as gold and silica. Each type exhibits distinct physicochemical advantages that contribute to stability, drug-loading capacity, and targeting efficacy. Engineered nanocarriers can be utilized for the active targeting of tumor-specific receptors or for passive targeting of tumors via the enhanced permeability (EPR) and retention effect, a characteristic of abnormal tumor vasculature. This targeting approach enables the precise delivery of the therapeutic agents at tumor sites, increasing drug efficacy while minimizing exposure to healthy tissues. The benefits of these strategies include reduced systemic adverse effects, improved bioavailability, and an optimized therapeutic index. This review examines both active and passive drug delivery systems, with a special focus on the characteristics of the EPR effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.